<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04499586</url>
  </required_header>
  <id_info>
    <org_study_id>FDRT-R006</org_study_id>
    <nct_id>NCT04499586</nct_id>
  </id_info>
  <brief_title>A Study of Radiotherapy Combined With Raltitrexed and Irinotecan in Metastatic or Locally Recurrent Colorectal Cancer</brief_title>
  <official_title>A Phase II Trial of Radiotherapy Combined With Raltitrexed and Irinotecan(CPT-11) in Patients With Metastatic or Locally Recurrent Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study evaluates the effectiveness of radiotherapy combined with raltitrexed and&#xD;
      irinotecan in treating patients who have metastatic or locally recurrent colorectal cancer&#xD;
      that has not responded to fluorouracil. The patients will receive radiotherapy combined with&#xD;
      raltitrexed and irinotecan, and then the surgeons will evaluate whether they should receive a&#xD;
      surgery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Actual">August 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR(Objective Response Rate) includes CR(Complete Rate) and PR(Partial Rate)</measure>
    <time_frame>20 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>DCR(Disease Control Rate)</measure>
    <time_frame>20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS(Progression Free Survival)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the morbidity of hematological adverse events and diarrhea as assessed by CTCAE v4.0</measure>
    <time_frame>20 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Recurrent Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Radiotherapy Combined With Raltitrexed and Irinotecan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each cycle lasts 3 weeks. Administration of Raltitrexed and Irinotecan weekly followed by a 2 week 'rest' period with no drug given. Raltitrexed is given by IV infusion at a dose of 3mg/m2. Irinotecan is given by IV infusion at a dose of 80mg/m2 (UGT1A1*28 6/6) or 65mg/m2 (UGT1A1*28 6/7).Radiation: 45-55Gy/25-30Fx</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Radiotherapy Combined With Raltitrexed and Irinotecan</intervention_name>
    <description>Each cycle lasts 3 weeks. Raltitrexed: 3mg/m2 per week. Irinotecan : 80mg/m2 (UGT1A1*28 6/6) or 65mg/m2 (UGT1A1*28 6/7) per week. Radiation: 45-55Gy/25-30Fx</description>
    <arm_group_label>Radiotherapy Combined With Raltitrexed and Irinotecan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically proven metastatic, advanced, or locally recurrent fluorouracil (5-FU)&#xD;
             and oxaliplatin refractory adenocarcinoma of the colon or rectum; Progression of&#xD;
             disease within 6 months of receiving adjuvant 5-FU and oxaliplatin chemotherapy OR&#xD;
             Progression of disease during or following completion of 5-FU and oxaliplatin&#xD;
             chemotherapy for metastatic disease&#xD;
&#xD;
          -  Evaluable lesions with indications of radiotherapy&#xD;
&#xD;
          -  No other metastatic lesions in the radiation field&#xD;
&#xD;
          -  Karnofsky Performance Status&gt;=70&#xD;
&#xD;
          -  UGT1A1*28 6/6 or 6/7&#xD;
&#xD;
          -  Subject blood routine and biochemical indicators meet the following criteria:&#xD;
             hemoglobin ≥ 90g / L; absolute neutrophil count (ANC) ≥ 1.5 × 109 / L; Alanine&#xD;
             transaminase (ALT), aspartate aminotransferase (AST) ≤ 2.5 times the upper limit of&#xD;
             normal; alkaline phosphatase (ALP) ≤2.5 times the normal upper limit; serum total&#xD;
             bilirubin &lt;1.5 times the normal upper limit; serum creatinine &lt;1 times the normal&#xD;
             upper limit; serum albumin ≥ 30g / L&#xD;
&#xD;
          -  Able to follow the protocol during the study period&#xD;
&#xD;
          -  Sign the inform consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
&#xD;
          -  If there is an uncontrolled history of epilepsy, central nervous system disease or&#xD;
             mental disorder, the investigator may determine that the clinical severity may hinder&#xD;
             the signing of informed consent or affect the patient's oral medication compliance.&#xD;
&#xD;
          -  Clinically severe (ie, active) heart disease, such as symptomatic coronary heart&#xD;
             disease, New York Heart Association (NYHA) class II or more severe congestive heart&#xD;
             failure or severe arrhythmia requiring medication intervention (see appendix 12), or a&#xD;
             history of myocardial infarction in the last 12 months&#xD;
&#xD;
          -  Organ transplantation requires immunosuppressive therapy&#xD;
&#xD;
          -  Severe uncontrolled recurrent infections, or other serious uncontrolled concomitant&#xD;
             diseases&#xD;
&#xD;
          -  Anyone who is allergic to any research medication&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhen Zhang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200023</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 31, 2020</study_first_submitted>
  <study_first_submitted_qc>July 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2020</study_first_posted>
  <last_update_submitted>July 31, 2020</last_update_submitted>
  <last_update_submitted_qc>July 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Zhu Ji</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>Recurrent Colorectal Cancer</keyword>
  <keyword>Irinotecan</keyword>
  <keyword>Raltitrexed</keyword>
  <keyword>Chemoradiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Raltitrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

